PET/CT in Psoriatic Arthritis

FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01654198

Enrollment

Registered

2012-07-31

Start date

2012-07-31

Completion date

2018-10-02

Last updated

2020-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.

Interventions

RADIATIONFDG-PET/CT scan

FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age 18-80, * active psoriatic arthritis (joint or enthesis inflammation)

Exclusion criteria

* Diabetes, * pregnant, * no active PsA

Design outcomes

Primary

Measure	Time frame
Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses.	At the discretion of the PI

Secondary

Measure	Time frame
Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP.	At the discretion of the PI

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026